1. Home
  2. FSTR vs LUNG Comparison

FSTR vs LUNG Comparison

Compare FSTR & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo L.B. Foster Company

FSTR

L.B. Foster Company

HOLD

Current Price

$38.40

Market Cap

308.9M

Sector

Industrials

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.54

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSTR
LUNG
Founded
1902
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
308.9M
57.9M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
FSTR
LUNG
Price
$38.40
$1.54
Analyst Decision
Hold
Buy
Analyst Count
1
7
Target Price
$32.00
$5.38
AVG Volume (30 Days)
114.2K
520.2K
Earning Date
05-04-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
0.14
N/A
Revenue
$540,009,000.00
$90,497,000.00
Revenue This Year
$5.12
$2.48
Revenue Next Year
$2.78
$18.46
P/E Ratio
$273.43
N/A
Revenue Growth
1.74
8.01
52 Week Low
$18.62
$1.13
52 Week High
$42.47
$3.88

Technical Indicators

Market Signals
Indicator
FSTR
LUNG
Relative Strength Index (RSI) 58.84 66.44
Support Level $26.06 $1.51
Resistance Level $42.47 $1.64
Average True Range (ATR) 1.80 0.09
MACD -0.41 0.04
Stochastic Oscillator 28.52 82.34

Price Performance

Historical Comparison
FSTR
LUNG

About FSTR L.B. Foster Company

L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: